Sensitivity analyses of duration between first and second cancer*
| Sensitivity analysis | Characteristic of primary cancer; HR* (95% CI) | |||||
|---|---|---|---|---|---|---|
| Any first cancer | Unrelated to tobacco use | Relation to tobacco use uncertain | Related to tobacco use | Diagnosed in childhood (< 14 yr) | Diagnosed in adulthood (≥ 14 yr) | |
| Risk of any second primary cancer | ||||||
| Period of exclusion, yr | ||||||
| No exclusion | 1.25 (1.24–1.26) | 1.09 (1.07–1.11) | 1.25 (1.24–1.26) | 1.29 (1.26–1.32) | 7.16 (0.62–13.7) | 1.27 (1.25–1.28) |
| 1 | 1.28 (1.26–1.30) | 1.14 (1.12–1.16) | 1.32 (1.31–1.34) | 1.32 (1.27–1.36) | 5.99 (2.49–9.51) | 1.28 (1.27–1.30) |
| 2 | 1.31 (1.29–1.33) | 1.17 (1.15–1.20) | 1.34 (1.32–1.36) | 1.34 (1.29–1.39) | 7.18 (0.86–13.5) | 1.31 (1.29–1.33) |
| 5 | 1.35 (1.33–1.39) | 1.26 (1.23–1.29) | 1.38 (1.36–1.41) | 1.39 (1.32–1.46) | 5.71 (1.67–9.74) | 1.36 (1.33–1.38) |
| 10 | 1.38 (1.34–1.43) | 1.31 (1.26–1.37) | 1.43 (1.39–1.48) | 1.36 (1.25–1.46) | 4.96 (1.35–8.57) | 1.38 (1.34–1.43) |
| Risk of same second primary cancer | ||||||
| Period of exclusion, yr | ||||||
| No exclusion | 2.16 (1.98–2.34) | 0.82 (0.77–0.87) | 2.33 (2.03–2.63) | 2.77 (2.03–2.63) | 184 (0.00–389) | 1.90 (1.73–2.07) |
| 1 | 2.25 (2.00–2.50) | 1.23 (1.16–1.30) | 2.28 (1.88–2.68) | 2.68 (2.22–3.15) | 82.4 (0.00–221) | 2.21 (1.90–2.53) |
| 2 | 2.28 (1.91–2.64) | 1.24 (1.17–1.32) | 2.22 (1.66–2.80) | 2.85 (2.21–3.49) | 110 (0.00–322) | 2.14 (1.83–2.44) |
| 5 | 2.58 (2.09–3.05) | 1.25 (1.16–1.34) | 2.49 (1.72–3.27) | 3.35 (2.54–4.16) | 528 (0.0–3407) | 2.59 (2.11–3.07) |
| 10 | 2.40 (2.00–2.80) | 1.60 (1.44–176) | 2.11 (1.58–2.64) | 3.22 (2.35–4.09) | – | 2.50 (1.94–3.06) |
| Risk of different second primary cancer | ||||||
| Period of exclusion, yr | ||||||
| No exclusion | 1.13 (1.12–1.15) | 0.97 (0.95–0.99) | 1.16 (1.15–1.18) | 1.20 (1.17–1.23) | 5.86 (1.17–10.6) | 1.17 (1.16–1.18) |
| 1 | 1.19 (1.17–1.20) | 1.05 (1.03–1.07) | 1.19 (1.18–1.21) | 1.26 (1.22–130) | 4.25 (1.60–6.89) | 1.18 (1.17–1.20) |
| 2 | 1.21 (1.19–1.23) | 1.07 (1.05–1.09) | 1.22 (1.19–1.23) | 1.28 (1.23–1.33) | 4.73 (1.88–7.59) | 1.21 (1.19–1.22) |
| 5 | 1.25 (1.23–1.28) | 1.14 (1.11–1.17) | 1.25 (1.23–1.28) | 1.32 (1.25–1.38) | 5.01 (0.0–10.9) | 1.25 (1.22–1.27) |
| 10 | 1.27 (1.23–1.31) | 1.17 (1.11–1.22) | 1.29 (1.12–1.33) | 1.31 (1.20–1.41) | 4.49 (0.37–8.62) | 1.26 (1.23–1.31) |
Note: CI = confidence interval, HR = hazard ratio.
↵* Values are based on fixed-effects aggregated HRs as in Figures 2, 3 and 4. Estimates were computed by excluding second primary cancers diagnosed 1, 2, 5 or 10 years after the diagnosis of the first primary cancer.